Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication.

Literature DB >> 7903556

Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication.

R Tandon¹, S C Ribeiro, J R DeQuardo, R S Goldman, J Goodson, J F Greden.

Abstract

Entities: Disease

Mesh：

Substances：
Antipsychotic Agents

Year: 1993 PMID： 7903556 DOI： 10.1016/0006-3223(93)90242-6

Source DB: PubMed Journal: Biol Psychiatry ISSN： 0006-3223 Impact factor: 13.382

Keyword Cloud
Cited

× No keyword cloud information.

7 in total

1. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

Authors: R Depoortère; L Bardin; A L Auclair; M S Kleven; E Prinssen; F Colpaert; B Vacher; A Newman-Tancredi
Journal: Br J Pharmacol Date: 2007-03-20 Impact factor: 8.739

2. The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia.

Authors: Stéphane Raffard; Catherine Bortolon; Hanan Yazbek; Christophe Lançon; Michel Benoit; Joanna Norton; Delphine Capdevielle
Journal: Eur Arch Psychiatry Clin Neurosci Date: 2018-06-08 Impact factor: 5.270

3. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

Authors: R Depoortère; A L Auclair; L Bardin; L Bruins Slot; M S Kleven; F Colpaert; B Vacher; A Newman-Tancredi
Journal: Br J Pharmacol Date: 2007-03-20 Impact factor: 8.739

Covariance of positive and negative symptoms during neuroleptic treatment in schizophrenia: a replication.

1. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. II. Activity in models of positive symptoms of schizophrenia.

2. The cognitive, affective motivational and clinical longitudinal determinants of apathy in schizophrenia.

3. F15063, a compound with D2/D3 antagonist, 5-HT 1A agonist and D4 partial agonist properties. III. Activity in models of cognition and negative symptoms.

4. Progesterone reduces hyperactivity of female and male dopamine transporter knockout mice.

5. Longitudinal progression of negative symptoms in schizophrenia: a new look at an old problem.

6. Pharmacotherapy for treatment-resistant schizophrenia.

Review 7. Recent advances in understanding schizophrenia.